BioXcel stock surges after completing pivotal Phase 3 trial

Published 01/08/2025, 14:04
© Reuters.

Investing.com -- BioXcel Therapeutics Inc (NASDAQ:BTAI) stock jumped 23.7% after announcing the completion of its pivotal Phase 3 SERENITY At-Home clinical trial for IGALMI® (dexmedetomidine).

The biopharmaceutical company, which utilizes artificial intelligence to develop neuroscience medicines, reported that the last patient visit has been completed in the study evaluating IGALMI for the treatment of agitation associated with bipolar disorders or schizophrenia in at-home settings. Topline data from the trial is expected to be released this month.

The Phase 3 trial enrolled more than 200 patients across 22 sites nationwide, with a balanced distribution between patients with bipolar disorders and schizophrenia. The double-blind, placebo-controlled study was designed to evaluate the safety of a 120 mcg dose of BXCL501 for acute treatment of agitation.

Results from the study are intended to support BioXcel’s planned supplemental New Drug Application (sNDA) to potentially expand IGALMI’s label for use in outpatient settings.

"This marks a major milestone in our efforts to bring a much-needed at-home treatment option to the millions of individuals who experience agitation related to bipolar disorders or schizophrenia," said Vimal Mehta, CEO of BioXcel Therapeutics.

According to the company, there are approximately 23 million episodes of bipolar or schizophrenia-related agitation annually in the U.S. that occur at home, with no FDA-approved therapies currently available for acute treatment in this setting.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.